|
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
CaT1 expression correlates with tumor grade in prostate cancer.
|
11401523 |
2001 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC).
|
12584203 |
2003 |
|
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues.
|
12480925 |
2002 |
|
Cardiovascular Diseases
|
0.110 |
GeneticVariation
|
group |
BEFREE |
The incidence of CVD has revealed a statistically significant dose response with the lack of a latent period and with the average ERR Gy = 0.47, 95% CI = 0.31, 0.63, p < 0.001.
|
28542008 |
2017 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction.
|
17325243 |
2007 |
|
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Contribution of SLC7A1 genetic variant to hypertension, the TAMRISK study.
|
23841815 |
2013 |
|
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension.
|
19067360 |
2009 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
The results of the present study indicate that miR-145 functions as a key mediator in the pathogenesis of hypertension via targeting SLC7A1, which suggests that miR-145 is a potential target for the treatment of hypertension.
|
29434681 |
2018 |
|
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We previously identified the polymorphism ss52051869 in the 3'UTR of human SLC7A1, and demonstrated that it might participate in the apparent link between altered endothelial function, decreased L-arginine and nitric oxide (NO) metabolism, and a genetic predisposition to essential hypertension.
|
19067360 |
2009 |
|
Essential Hypertension
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In vivo and in vitro measures of L-arginine transport were substantially reduced in the essential hypertension and positive family history groups compared with the negative family history group; however, no difference was detected in peripheral blood mononuclear cell mRNA or protein expression levels for the cationic amino acid transporter CAT-1.
|
15569830 |
2004 |
|
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The rs41318021 polymorphism in the SLC7A1 gene was not associated with essential hypertension in 50-year-old subjects.
|
23841815 |
2013 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These findings are the first to implicate a Ca(2+) channel in PCa progression and suggest that CaT1 may be a novel target for therapy.
|
11401523 |
2001 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC).
|
12584203 |
2003 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues.
|
12480925 |
2002 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines.
|
21308737 |
2011 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these results demonstrate that estrogen-inducible genes such as pS2 can be ERR targets and suggest that pharmacological modulation of ERRalpha activity may have therapeutic value in the treatment of breast cancer.
|
11559547 |
2001 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Here we show that ∼95% of cervical tumor samples examined overexpress Cat-1, suggesting that the up-regulation of Cat-1 expression is a frequent occurrence in this type of cancer.
|
22807447 |
2012 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies.
|
12480925 |
2002 |
|
Fetal Growth Retardation
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In summary, endothelium from fetuses with IUGR exhibit altered L-arginine transport and NO synthesis (L-arginine/NO pathway), reduced expression and activity of hCAT-1 and hCAT-2B and reduced eNOS activity.
|
12142345 |
2002 |
|
Fetal Growth Retardation
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Normal or IUGR HUVEC monolayers were exposed (0-24h) to 5% O(2) (normoxia), and 1 or 2% O(2) (hypoxia). l-Arginine transport and hCAT-1 expression, phosphorylated and total PKCalpha or eNOS protein and mRNA expression were quantified. eNOS involvement was tested using a siRNA against eNOS (eNOS-siRNA) adenovirus.
|
19501907 |
2009 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negatively regulating miR-219-1.
|
31478245 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negative-regulating miR-219-1.This article is protected by copyright.All rights reserved.
|
29231252 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negatively regulating miR-219-1.
|
31478245 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negative-regulating miR-219-1.This article is protected by copyright.All rights reserved.
|
29231252 |
2017 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these results demonstrate that estrogen-inducible genes such as pS2 can be ERR targets and suggest that pharmacological modulation of ERRalpha activity may have therapeutic value in the treatment of breast cancer.
|
11559547 |
2001 |